Lindy L Bancke1, Heather A Dworak2, Keith A Rodvold3, Mark B Halvorsen1, Barry E Gidal4. 1. Upsher-Smith Laboratories, Inc, Maple Grove, Minnesota, U.S.A. 2. Upsher-Smith Laboratories, Inc, Morristown, New Jersey, U.S.A. 3. Colleges of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, Illinois, U.S.A. 4. Department of Neurology, School of Pharmacy, University of Wisconsin, Madison, Wisconsin, U.S.A.
Abstract
OBJECTIVE: To compare the pharmacokinetics, pharmacodynamics, and tolerability of USL261, a midazolam formulation optimized for intranasal delivery, versus midazolam intravenous (IV) solution administered intranasally (MDZ-inj IN) or intravenously (MDZ-inj IV) in healthy adults. METHODS: In this phase 1, five-way crossover, open-label study, 25 healthy adults (aged 18-42 years) were randomly assigned to receive 2.5, 5.0, and 7.5 mg USL261; 2.5 mg MDZ-inj IV; and 5.0 mg MDZ-inj IN. Blood samples were collected for 12 h post dose to determine pharmacokinetic profiles. Pharmacodynamic assessments of sedation and psychomotor impairment also were conducted. Adverse events, oxygen saturation, and vital signs were recorded. RESULTS: Increasing USL261 dose corresponded with increases in midazolam area under the concentration time curve (AUC) and maximum observed plasma concentration (Cmax ), with all doses demonstrating rapid median time to Cmax (Tmax ; 10-12 min). USL261 also demonstrated increased absorption, with a 134% relative bioavailability, compared with the same MDZ-inj IN dose. USL261 was associated with dose-dependent increases in sedation and psychomotor impairment (p < 0.05); however, these effects lasted <4 h and generally did not differ from MDZ-inj IN or MDZ-inj IV at comparable doses. No serious adverse events (SAEs) or deaths were reported, and no treatment-emergent adverse events (TEAEs) led to study discontinuation. SIGNIFICANCE: Compared with intranasal delivery of a midazolam formulation intended for IV delivery, USL261, optimized for intranasal administration demonstrated improved bioavailability with similar pharmacodynamic effects. Therefore, USL261 may be a preferable alternative to the currently approved rectal diazepam treatment for intermittent bouts of increased seizure activity. Wiley Periodicals, Inc.
RCT Entities:
OBJECTIVE: To compare the pharmacokinetics, pharmacodynamics, and tolerability of USL261, a midazolam formulation optimized for intranasal delivery, versus midazolam intravenous (IV) solution administered intranasally (MDZ-inj IN) or intravenously (MDZ-inj IV) in healthy adults. METHODS: In this phase 1, five-way crossover, open-label study, 25 healthy adults (aged 18-42 years) were randomly assigned to receive 2.5, 5.0, and 7.5 mg USL261; 2.5 mg MDZ-inj IV; and 5.0 mg MDZ-inj IN. Blood samples were collected for 12 h post dose to determine pharmacokinetic profiles. Pharmacodynamic assessments of sedation and psychomotor impairment also were conducted. Adverse events, oxygen saturation, and vital signs were recorded. RESULTS: Increasing USL261 dose corresponded with increases in midazolam area under the concentration time curve (AUC) and maximum observed plasma concentration (Cmax ), with all doses demonstrating rapid median time to Cmax (Tmax ; 10-12 min). USL261 also demonstrated increased absorption, with a 134% relative bioavailability, compared with the same MDZ-inj IN dose. USL261 was associated with dose-dependent increases in sedation and psychomotor impairment (p < 0.05); however, these effects lasted <4 h and generally did not differ from MDZ-inj IN or MDZ-inj IV at comparable doses. No serious adverse events (SAEs) or deaths were reported, and no treatment-emergent adverse events (TEAEs) led to study discontinuation. SIGNIFICANCE: Compared with intranasal delivery of a midazolam formulation intended for IV delivery, USL261, optimized for intranasal administration demonstrated improved bioavailability with similar pharmacodynamic effects. Therefore, USL261 may be a preferable alternative to the currently approved rectal diazepam treatment for intermittent bouts of increased seizure activity. Wiley Periodicals, Inc.
Authors: Lenneke Schrier; Rob Zuiker; Frans W H M Merkus; Erica S Klaassen; Zheng Guan; Bert Tuk; Joop M A van Gerven; Ronald van der Geest; Geert Jan Groeneveld Journal: Br J Clin Pharmacol Date: 2016-12-20 Impact factor: 4.335
Authors: Daniel S Tsze; Maria Ieni; Daniel B Fenster; John Babineau; Joshua Kriger; Bruce Levin; Peter S Dayan Journal: Ann Emerg Med Date: 2016-11-04 Impact factor: 5.721
Authors: Davin Rautiola; Patricia D Maglalang; Narsihmulu Cheryala; Kathryn M Nelson; Gunda I Georg; Jared M Fine; Aleta L Svitak; Katherine A Faltesek; Leah R Hanson; Usha Mishra; Lisa D Coles; James C Cloyd; Ronald A Siegel Journal: J Pharmacol Exp Ther Date: 2019-03-05 Impact factor: 4.030
Authors: Anemone von Blomberg; Lara Kay; Susanne Knake; Sven Fuest; Johann Philipp Zöllner; Philipp S Reif; Eva Herrmann; Ümniye Balaban; Susanne Schubert-Bast; Felix Rosenow; Adam Strzelczyk Journal: CNS Drugs Date: 2020-05 Impact factor: 5.749
Authors: Kamil Detyniecki; Peter J Van Ess; David J Sequeira; James W Wheless; Tze-Chiang Meng; William E Pullman Journal: Epilepsia Date: 2019-05-29 Impact factor: 6.740